Dzangare J., Gonese E., Mugurungi O., Shamu T., Apollo T., Bennett D.E., Kelley K.F., Jordan M.R., Chakanyuka C., Cham F., Banda R.M.
Ministry of Health and Child Welfare, Harare, Zimbabwe; World Health Organization, Harare, Zimbabwe; Centers for Disease Control and Prevention, Atlanta, GA, United States; World Health Organization, Geneva, Switzerland; Tufts University School of Medicine, Boston, MA, United States; QUALABS Consulting Inc, Hartford, CT, United States; DTM and H, PGDip Dip in Health Economics, 123 Zomba Street, Area 10, Lilongwe, Malawi
Dzangare, J., Ministry of Health and Child Welfare, Harare, Zimbabwe; Gonese, E., Centers for Disease Control and Prevention, Atlanta, GA, United States; Mugurungi, O., Ministry of Health and Child Welfare, Harare, Zimbabwe; Shamu, T., Ministry of Health and Child Welfare, Harare, Zimbabwe; Apollo, T., Ministry of Health and Child Welfare, Harare, Zimbabwe; Bennett, D.E., Centers for Disease Control and Prevention, Atlanta, GA, United States; Kelley, K.F., World Health Organization, Geneva, Switzerland; Jordan, M.R., World Health Organization, Geneva, Switzerland, Tufts University School of Medicine, Boston, MA, United States; Chakanyuka, C., World Health Organization, Harare, Zimbabwe; Cham, F., QUALABS Consulting Inc, Hartford, CT, United States; Banda, R.M., World Health Organization, Harare, Zimbabwe, DTM and H, PGDip Dip in Health Economics, 123 Zomba Street, Area 10, Lilongwe, Malawi
Monitoring human immunodeficiency virus drug resistance (HIVDR) early warning indicators (EWIs) can help national antiretroviral treatment (ART) programs to identify clinic factors associated with HIVDR emergence and provide evidence to support national program and clinic-level adjustments, if necessary. World Health Organization-recommended HIVDR EWIs were monitored in Zimbabwe using routinely available data at selected ART clinics between 2007 and 2009. As Zimbabwe's national ART coverage increases, improved ART information systems are required to strengthen routine national ART monitoring and evaluation and facilitate scale-up of HIVDR EWI monitoring. Attention should be paid to minimizing loss to follow-up, supporting adherence, and ensuring clinic-level drug supply continuity.